Biktarvy demonstrates high efficacy for a broad range of people initiating treatment for HIV, including those with HBV coinfection

Interim data from the ALLIANCE trial evaluating Biktarvy in adults with HIV/HBV coinfection who were initiating therapy show potential suppression of HBV and HIV suppression comparable to an alternative HIV regimen. Additionally, 5-year data from two Phase III trials further demonstrated Biktarvy’s sustained efficacy, safety profile and high barrier to resistance in adults with HIV initiating therapy. The data were presented at the 24th International AIDS Conference (AIDS 2022).

Data from the ALLIANCE trial, which is an ongoing Phase III trial evaluating Biktarvy versus dolutegravir 50 mg (DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, F/TDF, DTG+F/TDF, demonstrated the efficacy of both antiretroviral regimens, in adults with HIV/HBV co-infection initiating treatment. The Week 48 results show Biktarvy demonstrated superior HBV DNA suppression. Importantly, participants who initiated treatment with Biktarvy versus DTG+F/TDF demonstrated superior HBV DNA suppression (<29 iu ml) (63% vs. 43%, p="0.0023)" and hepatitis b e-antigen (hbeag) seroconversion (23% vs. 11%, p="0.031)."></29>

The Week 48 results also showed that participants who initiated treatment with Biktarvy or DTG+F/TDF both had similarly high rates of HIV suppression (HIV-1 RNA <50 copies ml). participants who initiated treatment with biktarvy or dtg+f tdf both had high rates of hiv suppression at week 48 (95% vs. 91%; 95% ci - 2.5% to 10.8%, p="0.21)" with mean cd4 cell count increases of 200 and 175 cells ul from baseline, respectively. the alliance trial will continue in a blinded fashion through week 96 to determine longer-term safety and efficacy.></50>